Permira Is Said to Near Deal to Acquire U.K. Drugmaker Quotient

Permira is nearing a deal for drugmaker Quotient Sciences that values the U.K. firm at about 600 million pounds ($745 million) including debt, people familiar with the matter said.

The private equity firm is in advanced talks with Quotient’s owner, GHO Capital, and an acquisition could be announced in the coming days, the people said, asking not to be identified because the discussions are private. No final decisions have been made, they said.

A representative for Permira declined to comment. GHO Capital didn’t have an immediate comment.

Quotient helps companies develop new drugs, providing services such as formulation development, clinical ...